Tharp M D, Hoffman B B, Lefkowitz R J
J Clin Endocrinol Metab. 1981 Apr;52(4):709-14. doi: 10.1210/jcem-52-4-709.
The presence of alpha 2-adrenergic receptors in membranes derived from human sc adipose tissue was directly demonstrated with a new alpha 2-selective ligand, [3H]yohimbine. Binding of this radiolabeled antagonist to adipocyte membranes was of high affinity (Kd = 3.9 +/- 2.4 nM) and saturable. Computer modelling of [3H]yohimbine saturation curves demonstrated that it binds to a homogeneous class of sites with a density of 145.0 +/- 33.8 fmol/mg protein. Adrenergic agonists competed with [3H]yohimbine in the order expected of alpha-receptors, and their binding was strongly influenced by guanine nucleotides. Competition of alpha-antagonists with this radioligand demonstrated yohimbine to be more potent than prazosin, indicative of alpha 2-receptors. Antagonist binding was unaffected by guanine nucleotides. Paired saturation curves in these adipocyte membranes with the alpha 2-selective [3H]yohimbine and the nonsubtype selective alpha-antagonist [3H]dihydroergocryptine demonstrated similar receptor concentrations. [3H]Dihydroergocryptine has been previously shown to label both alpha 3- and alpha 2-receptors with equal affinity. Therefore, these data indicate that the vast majority of alpha-receptors in human sc fat are of the alpha 2-subtype. [3H]Yohimbine with its alpha 2-selectivity and high specific binding will provide an excellent tool for the clinical investigation of human adipocyte alpha-receptor mechanisms in both normal and pathological states.
利用一种新型α2选择性配体[3H]育亨宾直接证明了人皮下脂肪组织来源的细胞膜中存在α2肾上腺素能受体。这种放射性标记拮抗剂与脂肪细胞膜的结合具有高亲和力(Kd = 3.9 +/- 2.4 nM)且可饱和。[3H]育亨宾饱和曲线的计算机模拟表明,它与一类同质位点结合,密度为145.0 +/- 33.8 fmol/mg蛋白质。肾上腺素能激动剂按照α受体预期的顺序与[3H]育亨宾竞争,并且它们的结合受到鸟嘌呤核苷酸的强烈影响。α拮抗剂与这种放射性配体的竞争表明育亨宾比哌唑嗪更有效,表明存在α2受体。拮抗剂结合不受鸟嘌呤核苷酸影响。在这些脂肪细胞膜中,用α2选择性[3H]育亨宾和非亚型选择性α拮抗剂[3H]二氢麦角隐亭进行配对饱和曲线实验,结果显示受体浓度相似。先前已证明[3H]二氢麦角隐亭以相等的亲和力标记α3和α2受体。因此,这些数据表明人皮下脂肪中绝大多数α受体是α2亚型。具有α2选择性和高特异性结合的[3H]育亨宾将为正常和病理状态下人脂肪细胞α受体机制的临床研究提供一个极好的工具。